Potential therapeutic compounds that inhibit hERG, a potassium channel anti-target, have the propensity to cause cardiac arrhythmia (30), but no hERG potassium channel liability was observed with RDX8940 (<5% inhibition at 30 μM, manual patch clamp). Here, KCNH2 is linked to cardiac arrhythmia.